James W. Hodge
Laboratory of Tumor Immunology and Biology, CCR
National Cancer Institute
United States of America
Dr. James W. Hodge is a Senior Investigator and head of the Recombinant Vaccine Group in the Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, MD. Dr. Hodge received his Ph.D. in Comparative and Experimental Medicine from the University of Tennessee, and his MBA from the George Washington University. Dr. Hodge is active in the area of tumor immunity, and has made significant contributions to the design and development of novel recombinant vaccines and vaccine strategies for cancer immunotherapy including a) recombinant vectors to deliver tumor antigens, b) the use of costimulation to enhance antitumor T-cell responses, c) the combined use of vaccines with radiation, chemotherapy, and targeted small-molecule therapeutics. The concepts and therapeutics developed within the Recombinant Vaccine Group have been translated into many randomized multi-center trials at numerous Cancer Centers.
1) Immunotherapy 2) Cancer Vaccines 3) Radiation 4) Chemotherapy 5) Combination Therapies 6) Cytotoxic T-cells (CTL) 7) Cancer Biology, 8) Immunology
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses.
A triad of costimulatory molecules synergize to amplify T-cell activation.